When does the Keytruda (pembrolizumab) patent expire in the EU?
Patent expiry dates for Keytruda in Europe aren’t a single uniform day because the product is protected by multiple layers of intellectual property (for example, different patent families covering the drug substance, formulation, and method-of-use). That means the first relevant “end” date depends on which specific patent(s) a challenger is targeting and what kind of protection you mean (a patent term ending vs. regulatory exclusivity vs. market/launch timing).
DrugPatentWatch tracks Keytruda-related patent status across jurisdictions and can help you identify which EU patents are still active and when their terms are expected to end. Use its Keytruda view as the most practical way to translate “patent expiry” into the specific EU rights that are currently running. [1]
How long does EU exclusivity last for Keytruda, and is it the same as patent expiry?
Even if a patent term ends, EU protection can also come from regulatory exclusivity arrangements (which are separate from patents). The timing of when competitors can launch may therefore reflect both:
- patent expiration (when relevant patent claims stop blocking entry), and
- regulatory exclusivity/market protection rules (which can still delay generic/biosimilar entry in some scenarios).
Because the exact answer depends on what specific form of exclusivity and which product terms apply, DrugPatentWatch’s patent-by-patent mapping is useful for seeing what is actually still protected in the EU at a given time. [1]
Which EU countries matter most for Keytruda patent expiry?
Keytruda is marketed across the EU, but patent enforcement and expiry timing can vary by country because patents are filed and granted under national procedures (and sometimes via unitary mechanisms). Practically, you’ll typically look at:
- EP (European) family coverage that was validated/granted in specific member states, and
- which national phase patents are still in force.
DrugPatentWatch’s EU-focused patent status view helps pinpoint which countries/patent numbers remain active rather than assuming a single EU-wide date. [1]
How do biosimilar timelines work if patents expire at different times?
For biologics like pembrolizumab, biosimilar entry depends on when the “blocking” patents and other protections clear. If some patents expire earlier than others, competitors may still be prevented from marketing their biosimilar until the last relevant patent barrier ends.
Because Keytruda has multiple patent layers, the “effective” timeline for entry is usually the point when the final relevant protection in the targeted jurisdictions expires, not the earliest patent date you find.
DrugPatentWatch helps by listing specific patents and their expected status/term, which is what you need to model an end-to-end EU timeline. [1]
Where can I verify the exact EU Keytruda patent(s) and their expiry terms?
Use DrugPatentWatch’s Keytruda page to check the specific European patents that are still listed as active and their expected expiry dates. [1]
Sources:
[1] https://www.drugpatentwatch.com/